Bridging science, culture and capital from East and West to unlock human health.
We empower the next global biotech and medtech leaders.
2016
Established in 2016 with a global team of 10+ specialized experts in science, medicine and business.
4
4 portfolio funds fully deployed. Fund 1 has achieved a full exit with outstanding performance.
30
Portfolio companies in Singapore, China and the US.
We look for breakthroughs and build with trust, curiosity and care.
We believe that innovation is global with regional strengths, and back entrepreneurs and scientists hindered by market dislocations, cultural barriers and geopolitics.
1
From key hub cities, we connect to Asia’s deep talent, clinical resources and supply networks to turn science into scalable healthcare ventures.
2
We plan for global impact and outcomes from day one – working towards IPOs, acquisitions, and partnerships that create value and better health.
3
Pioneering innovation together with you.
Partners
-
Founding Partner, Singapore / Beijing
Ms. Summer Qu is the founder of Wedo Capital and an entrepreneurial investor with over a decade of venture capital experience. Before founding Wedo, she served as Executive Director at Northern Light Venture Capital, where she led the angel investment in Burning Rock (NASDAQ) and the Series A investment in GigaDevice (SSE). She has managed multi-billion-RMB dual-currency funds focused on deep technology and cross-border early-stage innovation.
Ms. Qu holds an M.B.A. from the Wharton School and has extensive experience in China’s healthcare technology investment landscape.
-
Partner, Singapore
Dr Xinhong Lim is a Stanford-trained scientist turned deep-tech and life sciences investor. As Managing Director at Vickers Venture Partners, he established the firm’s Silicon Valley office, helped raise and deploy more than USD 300 million, led investments including Aardvark (NASDAQ: AARD), and served on multiple Boards and as Chief Strategy Officer of an advanced materials portfolio company.
Before entering venture capital, Dr. Lim was an award-winning Principal Investigator at A*STAR in Singapore, with publications in Nature and Science, and previously served as M.D. of the founding team for Bhutan’s Gelephu Mindfulness City.
-
Venture Partner, California / Shenzhen
Ms. Mu Ni brings over 25 years of experience as an entrepreneur, investor, and corporate leader with deep M&A and board expertise. She was a key investor in Alibaba’s IPO, and her portfolio spans biotech, SaaS, and semiconductors. Ms. Ni focuses on fundraising.
Ms. Ni holds an M.B.A. from Peking University and has served in leadership roles with national organizations, including the All-China Youth Federation.
-
Venture Partner, Beijing
Mr. Yun Sam Wu has over 22 years of experience in investment and finance, including nine years as Executive Director at The Carlyle Group. As an Investment Committee member at Wedo, he brings deep expertise across private and public equity markets.
Mr. Wu’s representative investments include Biocytogen (2315.HK).
Team
-
M.D., Beijing / Hong Kong
Ms. Xiaomeng Marina Guo is a specialist in medtech incubation with eight years of experience spanning early-stage startups and corporate innovation. She was a former healthcare lead at CITIC Trust and Peking University Health Science Center Industry Group.
Ms. Guo holds a B.Clin.Med from Peking University and an M.P.H. from University of Alabama-Birmingham. She is a Certified Technology Manager focused on portfolio incubation and scaling.
-
M.D., Shanghai / Suzhou
Ms. Hui Kang is a physician-scientist turned investor with deep expertise in clinical research, molecular biology, and next-generation sequencing. She co-founded OrigiMed and previously held roles as Project Scientist at Thermo Fisher and Clinical Trial Manager at MicroPort.
A Shanghai Jiaotong University M.Med and former Ph.D. candidate at the Max Planck Institute, Ms. Kang focuses on foundational life science technologies.
-
M.D., Hong Kong
Ms. Leilei Wang is a venture investor with over eight years of experience in VC, following a career in international banking and technology entrepreneurship. She previously served as a Global Banking Associate at HSBC in Hong Kong and New York, and co-founded two technology startups.Ms. Wang holds a B.A. in Economics from Peking University and an M.B.A. from the Wharton School.
-
M.D., Beijing / Hong Kong
Ms. Heng Flora Li brings over 20 years of cross-sector experience spanning Big Four audit, Fortune 500 finance, M&A, and fund operations. She held leadership roles as Financial Controller at a Schneider subsidiary and at ABB’s China headquarters. In addition to her Finance roles, Ms Li oversees risk control and compliance.
Ms. Li is a Certified Public Accountant (CPA) and Certified Internal Auditor (CIA). -
E.D., Beijing / Hong Kong
Mr. Dong Chen brings over 15 years of experience across global FMCG marketing, public equity, and venture investing. He was a Partner and Consumer & Utility Analyst at Tengyue Partners, with earlier roles at P&G and PepsiCo.
Mr. Chen holds a B.A. in Finance from Renmin University and an M.B.A. from the Wharton School.
-
E.D., Beijing / Singapore
Mr. Baikuan Clint Guo is a venture investor with a strong technical foundation in medical devices and AI research and development. A former GE Healthcare engineer and graduate of the Edison Engineering Development Program (EEDP), he now serves as Interim CEO of a portfolio company, leading its incubation and commercialization.
Mr. Guo holds a B.S. and M.S. in Biomedical Engineering from Tianjin University. -
V.P., Beijing / Singapore
Ms. Mengmeng Du is an engineer-turned-investor with experience in medical device development and venture building. She previously served as a Systems Engineer at GE Healthcare and was selected for the Edison Engineering Development Program (EEDP).
Ms. Du holds an M.S. in Engineering from Purdue University and currently serves as Interim COO of a portfolio company.
Investments that matter
BioPerfectus
(SSE:688399)
Molecular diagnostics leader for infectious and related diseases.
China
Fully-Exited
Series B
Bridgene Biosciences
Clinical stage AI + covalent small molecule chemical binders to drug high-value yet previously undruggable targets.
US
China
Series A
Huixin Lifetech
World-leading exosomal purification, diagnosis and biomaterial generation platform company.
huixinbio.com
US
China
Pre-Series A
Drugfarm
Clinical stage first-in-class modulators of ALPK1 to target heart and kidney disease, Alzheimer's, hepatitis B, and ROSAH syndrome.
US
China
Pre-Series B
Biocytogen
(SSE: 688796; 02315.HK)
Global leader in preclinical research models and proprietary human antibody discovery.
China
Geneus
World-leading fourth-generation nanopore gene sequencer.
China
Series A
Pre-Series B
Hemacell
Clinical stage company using blood stem cells for cell therapy, drug delivery and new drug development.
xuejibio.com
China
Angel
Pre-Series A
Series A
Reforgene
Clinical stage gene editing therapy for blood, liver and eye diseases.
reforgene.com
China
Pre-Series A